This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Raj Makkar, MD, vice president of Cardiovascular Innovation and Intervention and the director of the Karsh Division of Interventional Cardiology in the Smidt Heart Institute at Cedars-Sinai, and his team of experts treat more than 10,000 patients every year. When might a minimally invasive procedure be the best approach?
Evolut FX+ provides increased space for catheter maneuverability to facilitate access to coronary arteries of varying patient anatomies. This is reinforced by our continued innovation of the Evolut TAVR platform, which has delivered proven valve performance and durability to physicians and patients for years.
Deep venous anatomy and obstructions can present a multitude of complexities and mechanical challenges. Engineered for the unique demands of venous anatomy and obstructions, the Duo Venous Stent System is comprised of two stents – Duo Hybrid and Duo Extend – of various sizes. It is the third most common cardiovascular disease [2].
Data from the TRILUMINATE Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one year. are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S
Raj Makkar, MD, vice president of Cardiovascular Innovation and Intervention and the director of the Karsh Division of Interventional Cardiology in the Smidt Heart Institute at Cedars-Sinai, and his team of experts treat more than 10,000 patients every year. When might a minimally invasive procedure be the best approach?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content